Childhood Hematopoietic Cell Transplantation (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (12/02/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Allogeneic Hematopoietic Cell Transplantation (HCT)

Added text about published studies that compared outcomes for unrelated cord blood recipients with outcomes for recipients of bone marrow (cited Milano et al., Ruggeri et al., Bachanova et al., Sutton et al., and Sanchez-Garcia et al. as references 43, 44, 45, 46, and 47, respectively).

Complications After HCT

Added text to state that one study demonstrated a much higher chance of long-term graft-versus-host disease (GVHD)-free survival and lower treatment-related mortality in children with mild and moderate chronic GVHD than in children with severe chronic GVHD. At 8 years, the probability of continued chronic GVHD in children with mild, moderate, and severe chronic GVHD was 4%, 11%, and 36%, respectively (cited Inagaki et al. as reference 62).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Current Clinical Trials

Next section >
About This PDQ Summary